Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma
Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma
Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with
 persistent asthma.
Inclusion Criteria:

 -  Generally healthy men and women with persistent asthma, 18 to 70 years of age, with
 body weight between 50 kg and 115 kg.

 -  History of treatment with a medium to high dose of inhaled corticosteroids (ICS), with
 or without long-acting beta-agonists (LABA), for at least 2 months prior to the
 screening visit and must remain constant during the study.

 -  FEV1 ≥ 55% to ≤ 80% predicted and demonstrated improvement in FEV1 (L) with inhaled
 albuterol (salbutamol) (reversibility) of ≥ 12%.

 Exclusion Criteria: